Radiopharm Theranostics - Public Comps and Valuation Multiples

Radiopharm Theranostics Overview

About Radiopharm Theranostics

Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.

Founded

2021

HQ

Employees

Website

radiopharmtheranostics.com

Sectors

Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $2.1M

Last FY EBITDA -$24.9M

EV

$37.3M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Radiopharm Theranostics Financials

As of September 2025, Radiopharm Theranostics reported last 12-month revenue of $2.1M.

In the same period, Radiopharm Theranostics generated $1.0M in LTM gross profit and -$27.4M in net income.

See Radiopharm Theranostics valuation multiples based on analyst estimates

Radiopharm Theranostics P&L

In the most recent fiscal year, Radiopharm Theranostics reported revenue of $2.4M and EBITDA of -$24.9M.

Radiopharm Theranostics expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Radiopharm Theranostics valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$2.1M	XXX	$2.4M	XXX	XXX	XXX
Gross Profit	$1.0M	XXX	$26K	XXX	XXX	XXX
Gross Margin	48%	XXX	1%	XXX	XXX	XXX
EBITDA	n/a	XXX	-$24.9M	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	-1050%	XXX	XXX	XXX
EBIT	-$28.6M	XXX	-$22.6M	XXX	XXX	XXX
EBIT Margin	-1378%	XXX	-953%	XXX	XXX	XXX
Net Profit	-$27.4M	XXX	-$25.0M	XXX	XXX	XXX
Net Margin	-1319%	XXX	-1055%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Radiopharm Theranostics including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $2.1M. In the most recent fiscal year, Radiopharm Theranostics achieved $2.4M in revenue and -$24.9M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$2.1M	Analyst estimates available to subscribers	$2.4M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$1.0M	Analyst estimates available to subscribers	$26K	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	47.6% gross margin	Analyst estimates available to subscribers	1.1% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	n/a	Analyst estimates available to subscribers	-$24.9M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	n/a	Analyst estimates available to subscribers	-1050.4% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	-$28.6M	Analyst estimates available to subscribers	-$22.6M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	-1378.0% EBIT margin	Analyst estimates available to subscribers	-953.4% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	-$27.4M	Analyst estimates available to subscribers	-$25.0M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	-1319.4% net profit margin	Analyst estimates available to subscribers	-1055.3% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Radiopharm Theranostics

This financial data table provides comprehensive performance metrics for Radiopharm Theranostics, a company based in Australia. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Radiopharm Theranostics generated $2.1M in revenue over the last twelve months.
Gross profit for the last twelve months was $1.0M.
Net income over the last twelve months reached -$27.4M.

Fiscal Year Performance

In the most recent fiscal year, Radiopharm Theranostics reported $2.4M in total revenue.
Fiscal year EBITDA was -$24.9M.
The company maintained a gross profit margin of 1.1% in the most recent fiscal year.
EBITDA margin for the fiscal year was -1050.4%.
Net profit margin reached -1055.3% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Radiopharm Theranostics. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Radiopharm Theranostics Stock Performance

Radiopharm Theranostics has current market cap of AUD 86.4M (or $56.2M), and EV of AUD 57.2M (or $37.3M).

Market Cap Evolution

Radiopharm Theranostics Stock Data

As of October 17, 2025, Radiopharm Theranostics's stock price is AUD 0 (or $0).

See Radiopharm Theranostics trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$37.3M	$56.2M	XXX	XXX	XXX	XXX	$-0.01

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Radiopharm Theranostics Valuation Multiples

Radiopharm Theranostics's trades at 29.1x EV/Revenue multiple, and -1.4x EV/EBITDA.

See valuation multiples for Radiopharm Theranostics and 15K+ public comps

Radiopharm Theranostics Financial Valuation Multiples

As of October 17, 2025, Radiopharm Theranostics has market cap of $56.2M and EV of $37.3M.

Equity research analysts estimate Radiopharm Theranostics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Radiopharm Theranostics has a P/E ratio of -2.1x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$56.2M	XXX	$56.2M	XXX	XXX	XXX
EV (current)	$37.3M	XXX	$37.3M	XXX	XXX	XXX
EV/Revenue	18.0x	XXX	29.1x	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	-1.4x	XXX	XXX	XXX
EV/EBIT	-1.3x	XXX	-1.6x	XXX	XXX	XXX
EV/Gross Profit	37.7x	XXX	n/a	XXX	XXX	XXX
P/E	-2.1x	XXX	-2.0x	XXX	XXX	XXX
EV/FCF	n/a	XXX	-1.9x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Radiopharm Theranostics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Radiopharm Theranostics Margins & Growth Rates

Radiopharm Theranostics's last 12 month revenue growth is -53%

Radiopharm Theranostics's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $1.6M for the same period.

Radiopharm Theranostics's rule of 40 is -2144% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Radiopharm Theranostics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Radiopharm Theranostics and other 15K+ public comps

Radiopharm Theranostics Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	-53%	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	-2091%	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	-2144%	XXX	-2144%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.2M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$1.6M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	757%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	954%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial